Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have
been treated with a combination therapy of trabectedin and irinotecan (within compassionate
use), to determine, if this is a promising treatment option with acceptable toxicity and if
the results warrant a prospective study.